PharmaSGP Holding SE
PharmaSGP Holding SE manufactures and sells over-the-counter drugs and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage creams for the treatment of various pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil … Read more
PharmaSGP Holding SE (PSG) - Net Assets
Latest net assets as of March 2025: €36.67 Million EUR
Based on the latest financial reports, PharmaSGP Holding SE (PSG) has net assets worth €36.67 Million EUR as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€118.18 Million) and total liabilities (€81.51 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €36.67 Million |
| % of Total Assets | 31.03% |
| Annual Growth Rate | -4.04% |
| 5-Year Change | 177.76% |
| 10-Year Change | N/A |
| Growth Volatility | 47.7 |
PharmaSGP Holding SE - Net Assets Trend (2014–2024)
This chart illustrates how PharmaSGP Holding SE's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PharmaSGP Holding SE (2014–2024)
The table below shows the annual net assets of PharmaSGP Holding SE from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €31.96 Million | -19.60% |
| 2023-12-31 | €39.75 Million | +27.84% |
| 2022-12-31 | €31.10 Million | +40.10% |
| 2021-12-31 | €22.20 Million | +92.90% |
| 2020-12-31 | €11.51 Million | -87.96% |
| 2019-12-31 | €95.58 Million | +55.88% |
| 2017-12-31 | €61.32 Million | +6.58% |
| 2016-12-31 | €57.53 Million | +6.96% |
| 2015-12-31 | €53.79 Million | +11.44% |
| 2014-12-31 | €48.27 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to PharmaSGP Holding SE's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 124.7% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €39.58 Million | 123.84% |
| Total Equity | €31.96 Million | 100.00% |
PharmaSGP Holding SE Competitors by Market Cap
The table below lists competitors of PharmaSGP Holding SE ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TPC Mechatronics Corporation
KQ:048770
|
$17.11 Million |
|
Selva Gida Sanayi AS
IS:SELVA
|
$17.11 Million |
|
Kainos Medicine Inc
KQ:284620
|
$17.12 Million |
|
Southern Energy Corp
V:SOU
|
$17.12 Million |
|
HeraMED Limited
F:1I4
|
$17.10 Million |
|
Modulight Oyj
HE:MODU
|
$17.10 Million |
|
Rigolleau SA
BA:RIGO
|
$17.09 Million |
|
Manba Finance Ltd
NSE:MANBA
|
$17.08 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PharmaSGP Holding SE's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 39,754,000 to 31,962,000, a change of -7,792,000 (-19.6%).
- Net income of 19,535,000 contributed positively to equity growth.
- Dividend payments of 16,307,000 reduced retained earnings.
- Share repurchases of 10,358,000 reduced equity.
- Other factors decreased equity by 662,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €19.54 Million | +61.12% |
| Dividends Paid | €16.31 Million | -51.02% |
| Share Repurchases | €10.36 Million | -32.41% |
| Other Changes | €-662.00K | -2.07% |
| Total Change | €- | -19.60% |
Book Value vs Market Value Analysis
This analysis compares PharmaSGP Holding SE's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 10.37x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.62x to 10.37x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | €7.97 | €28.80 | x |
| 2020-12-31 | €0.96 | €28.80 | x |
| 2021-12-31 | €1.85 | €28.80 | x |
| 2022-12-31 | €2.59 | €28.80 | x |
| 2023-12-31 | €3.32 | €28.80 | x |
| 2024-12-31 | €2.78 | €28.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PharmaSGP Holding SE utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 61.12%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.44%
- • Asset Turnover: 1.04x
- • Equity Multiplier: 3.58x
- Recent ROE (61.12%) is above the historical average (33.23%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 5.54% | 4.39% | 0.89x | 1.42x | €-2.15 Million |
| 2015 | 12.89% | 8.86% | 1.01x | 1.44x | €1.55 Million |
| 2016 | 9.01% | 6.31% | 1.03x | 1.39x | €-570.30K |
| 2017 | 5.91% | 4.50% | 0.97x | 1.36x | €-2.51 Million |
| 2019 | 17.48% | 26.70% | 0.60x | 1.09x | €7.15 Million |
| 2020 | 92.47% | 16.82% | 2.54x | 2.17x | €9.49 Million |
| 2021 | 48.16% | 16.36% | 0.57x | 5.19x | €8.47 Million |
| 2022 | 38.44% | 13.93% | 0.66x | 4.15x | €8.84 Million |
| 2023 | 41.25% | 16.22% | 0.77x | 3.30x | €12.42 Million |
| 2024 | 61.12% | 16.44% | 1.04x | 3.58x | €16.34 Million |
Industry Comparison
This section compares PharmaSGP Holding SE's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PharmaSGP Holding SE (PSG) | €36.67 Million | 5.54% | 2.22x | $17.11 Million |
| Hanna Capital Corp (04U1) | $-79.29K | 0.00% | 0.00x | $116.52K |
| WESTMINSTER RES (08W) | $5.62 Million | -3.29% | 0.10x | $5.16 Million |
| Axonics Inc (0I3) | $482.44 Million | -16.60% | 0.14x | $3.29 Billion |
| Global Bioenergies SA (1DK) | $9.23 Million | -118.16% | 1.79x | $369.68K |
| GIEAG Immobilien AG (2GI) | $68.16 Million | -4.05% | 4.40x | $14.69K |
| 2invest AG (2INV) | $84.50 Million | 65.13% | 0.01x | $13.67 Million |
| PT Central Proteina Prima Tbk (4PT) | $3.18 Trillion | 11.74% | 1.15x | $6.90 Million |
| Eurobattery Minerals AB (5KD) | $57.72 Million | -326.44% | 2.20x | $77.17 Million |
| DGH Deutsche Grundwert Holding AG (5TR) | $0.00 | 0.00% | 0.00x | $16.88K |
| SOFTCHOICE CORP. (90Q) | $-27.47 Million | 0.00% | 0.00x | $470.36 Million |